Method of reducing somnolence in patients treated with tizanidine
Patent 6455557 Issued on September 24, 2002. Estimated Expiration Date: November 28, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Other References
Hutchinson, D.E.; Modified Release of Tizanidine, A Review; vol. 17, No. 5, pp. 565-573 (1989).
Holtebeck, B., "Tizanidine: An alternative in the Pharmacologic Treatment of Spasticity," Journal of the Pharmacy Society of Wisconsin, Mar./Apr. 2000: 26-31 (2000)
Young, R., "Tizanidine and spasticity," Neurology 45(12);2296-2296 (1995)
Roberts, R.C., et al., "Pharmacokinetics and pharmacodynamics of tizanidine," Neurology 44 (Supp 9): S29-S31 (1994)
Wallace, J.D., "Summary of combined clinical trials analysis of controlled clinical trials with tizanidine," Neurology 44(Supp 9): S60-S68 (1994)
Shellenberger, M.K., et al., "A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state," Drug Metabolism and Distribution 27(2): 201-204 (1999)
Wagstaff et al., Tizanidine, "A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Spasticity Associated with Cerebral and Spinal Disorders," ADIS Drug Evaluation, Drugs, 53(3), pp. 435-452 (Mar. 1997)
Wesnes et al., "Effects of Sibutramine alone and with alcohol on cognitive function in healthy volunteers," British Journal of Clinical Pharmacology, 49, pp. 110-117 (2000)
Simpson et al., "The Cognitive Drug Research Computerized Assessment System for Demented Patients: A Validation Study, International Journal of Geriatric Psychiatry," International Journal of Geriatric Psychiatry, vol. 6, pp. 95-102 (1991)
Chapleo et al., "Heteroaromatic Analogues of the 2 -Adrenoreceptor Partial Agonist Clonidine," J. Med. Chem, 32, pp. 1627-1630 (1989)
Smith et al., "Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population, American Journal of Hospice & Palliative Care," American Journal of Hospice& Palliative Care, 17(1), pp. 50-58 (Jan.-Feb. 2000
November 28, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
